ClinicalTrials.gg
RecruitingNCT06804811Updated Oct 9, 2026

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in NonSegmental Vitiligo, sponsored by Incyte Corporation. Recruiting at 78 sites in 14 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 9, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Planned enrollment
4th of 14
250 · median 90
Started
2025
with 2 others
Phase 3
6 of 14
3 open now
Registered
11th of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 11th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

03

Conditions studied

  • NonSegmental Vitiligo

Browse trials for

Keywords

  • NonSegmental Vitiligo
  • pediatric
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 to \< 12 years at the time of signing the ICF.
  • Clinical diagnosis of nonsegmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI.
  • Total body vitiligo area does not exceed 10% BSA.
  • Pigmented hair within some of the areas of vitiligo on the face.
  • Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit.
  • For sexually active participants (except participants who are prepubescent) willingness to avoid pregnancy or fathering a child as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other forms of vitiligo (eg, segmental).
  • Other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study drug application or study assessments.
  • Prior or current use of depigmentation treatments (eg, monobenzone).
  • Concurrent conditions and history of protocol-defined diseases
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of protocol-defined treatments within the indicated before baseline.
  • History of treatment failure with any systemic or topical JAK inhibitor for vitiligo or any other inflammatory condition.
  • Protocol-defined abnormal laboratory values at screening.
  • -for-age \< 5th percentile or ≥ 85th percentile according to the CDC BMI Percentile Calculator for Child and Teen.
  • Pregnant or lactating participants or those considering pregnancy during the period of their study participation.
  • In the opinion of the investigator, unable or unlikely to comply with the application schedule and study evaluations.
  • Living with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
  • Employees of the sponsor or investigator or are otherwise dependents of them.
  • Known allergy or reaction to any component of the study cream formulation.
  • The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health code.
  • In the EU, participants considered incapacitated according to EU CTR No. 536/2014 Articles 2 and 31.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Ruxolitinib 0.75 % Cream

    Participants received ruxolitinib 0.75% cream, applied topically to the affected area as defined in the protocol.

    Drug: Ruxolitinib Cream

  • Experimental
    Ruxolitinib 1.5 % Cream

    Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.

    Drug: Ruxolitinib Cream

  • Placebo comparator
    Vehicle Cream

    Participants received vehicle cream, applied topically to the affected area as defined by the protocol.

    Drug: Vehicle Cream

Interventions

  • Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

    Also known as: INCB018424 Phosphate Cream

  • DrugVehicle Cream

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)

    ≥75% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 24

Secondary outcomes

  1. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI50)

    ≥50% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 24

  2. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI90)

    ≥90% improvement in facial Vitiligo Area Scoring Index.

    Time frame: Week 24

  3. Proportion of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50)

    ≥50% improvement in total body Vitiligo Area Scoring Index.

    Time frame: Week 24

  4. Percentage change from baseline in F-BSA

    Facial body surface area (F-BSA) takes into account the facial depigmented areas as a percentage of the total body area.

    Time frame: Week 24

  5. Number of Treatment Emergent Adverse Events (TEAEs)

    TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to Week 52 and 30 days

  6. Proportion of participants achieving a Vitiligo Noticeability Scale (VNS) score of 4 (a lot less noticeable) or 5 (no longer noticeable)

    The VNS is a patient-reported measure of vitiligo treatment success that has a 5-point scale.

    Time frame: Week 24 and Week 52

  7. Proportion of participants in each category for the color-matching question

    The color-matching question is a patient-reported measure of vitiligo treatment success that has a 5-point scale.

    Time frame: Week 24 and Week 52

  8. Proportion of participants who report facial assessment of Patient Global Impression of Change-Vitiligo (F-PaGIC-V) of very much improved or much improved

    The F-PaGIC-V is an assessment of improvement by the participant that has a 7-point scale.

    Time frame: Week 24 and Week 52

  9. Proportion of participants who report total body assessment of Patient Global Impression of Change-Vitiligo (T-PaGIC-V) of very much improved or much improved

    The T-PaGIC-V is an assessment of improvement by the participant that has a 7-point scale.

    Time frame: Week 24 and Week 52

  10. Change from baseline in Psychosocial Impact Questionnaire for Pediatric Patients Who Have Nonsegmental Vitiligo (VIT-PIQ)

    The VIT-PIQ is a 17-item questionnaire to assess Quality of Life (QOL) of children with vitiligo.

    Time frame: Week 24 and Week 52

  11. Change from baseline in Children's Dermatology Life Quality Index (CDLQI)

    The CDLQI is the youth/children's version of the Dermatology Life Quality Index.

    Time frame: Week 24 and Week 52

  12. Change from baseline in Patient Global Impression of Bother - Vitiligo (PGIB-V)

    The PGIB-V is a single question with an 11-point scale ("not at all" to "a whole lot") to assess the participant's level of bother because of their vitiligo.

    Time frame: Week 24 and Week 52

  13. Mean satisfaction score

    The treatment satisfaction tool is a fit-for-purpose questionnaire to assess treatment satisfaction in children with nonsegmental vitiligo.

    Time frame: Week 24 and Week 52

  14. Pharmacokinetic (PK) of Ruxolitinib: Trough concentrations

    Trough is defined as the concentration reached by a drug immediately before the next dose is administered.

    Time frame: Weeks 6, 24, 30 and 52

07

Study locations

78 of 78 sites recruiting
  • Psoriahue
    Buenos Aires, 01425, Argentina
    Recruiting
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1181ACH, Argentina
    Recruiting
  • Instituto de Neumonologia Y Dermatologia
    Buenos Aires, C1425BEA, Argentina
    Recruiting
  • Consultorios Medicos Dr. Doreski
    Buenos Aires, C1426ABP, Argentina
    Recruiting
  • Derma Internacional S.A.
    Buenos Aires, C1426, Argentina
    Recruiting
  • Hospital Universitario Austral
    Derqui-pilar, B16290DT, Argentina
    Recruiting
  • Centro de Investigaciones Medicas Mar Del Plata
    Mar del Plata, B7600FYK, Argentina
    Recruiting
  • Hospital Del Nino Jesus
    San Miguel de Tucumán, 04000, Argentina
    Recruiting
  • Universitaetsklinikum Graz
    Graz, 08036, Austria
    Recruiting
  • Medical University Innsbruck
    Innsbruck, 06020, Austria
    Recruiting
  • Hopital Universitaire de Bruxelles (Academisch Ziekenhuis Brussel)
    Brussels, 01070, Belgium
    Recruiting
  • Universitair Ziekenhuis Gent
    Ghent, 09000, Belgium
    Recruiting
  • Universitair Ziekenhuis Leuven
    Leuven, 03000, Belgium
    Recruiting
  • Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc
    Woluwe-Saint-Lambert, 01200, Belgium
    Recruiting
  • Medical Center Asklepii Ood
    Dupnitsa, 02600, Bulgaria
    Recruiting
  • Mhat Dr. Tota Venkova Ad
    Gabrovo, 05300, Bulgaria
    Recruiting
  • Medical Center Unimed Eood
    Sevlievo, 05400, Bulgaria
    Recruiting
  • Umhat Aleksandrovska
    Sofia, 01431, Bulgaria
    Recruiting
  • 28 Diagnostic and Consultative Center
    Sofia, 01528, Bulgaria
    Recruiting
  • Mc Euroderma Clinic
    Sofia, 01606, Bulgaria
    Recruiting
  • Diagnostic Consultation Center Xx - Sofia Eood
    Sofia, 01618, Bulgaria
    Recruiting
  • Herlev and Gentofte Hospital
    Hellerup, 02900, Denmark
    Recruiting
  • Sanos Clinic
    Herlev, 02730, Denmark
    Recruiting
  • Centre Hospitalier Victor Dupouy
    Argenteuil, 95107, France
    Recruiting
  • Centre Hospitalier Universitaire (Chu) de Bordeaux - Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
    Recruiting
  • Centre Hospitalier Intercommunal de Creteil
    Créteil, 75571, France
    Recruiting
  • Hospices Civils de Lyon (Hcl) - Hopital Edouard Herriot (Heh)
    Lyon, 69003, France
    Recruiting
  • Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hopital Hotel Dieu
    Nantes, 44093, France
    Recruiting
  • Centre Hospitalier Universitaire de Nice,Hopital L Archet
    Nice, 06200, France
    Recruiting
  • Hopital Universitaire Necker Enfants Malades
    Paris, 75015, France
    Recruiting
  • Polyclinique de Courlancy
    Reims, 51100, France
    Recruiting
  • Centre Hospitalier Universitaire (Chu) de Toulouse - Hopital Larrey
    Toulouse, 31059, France
    Recruiting
  • Chu Nancy
    Vandœuvre-lès-Nancy, 54500, France
    Recruiting
  • Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (Ccm)
    Berlin, 10117, Germany
    Recruiting
  • Hautklinik Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
    Recruiting
  • Katholisches Kinderkrankenhaus Wilhelmstift
    Hamburg, 22149, Germany
    Recruiting
  • University Medical Center Schleswig-Holstein
    Kiel, 24105, Germany
    Recruiting
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
    Recruiting
  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
    Mainz, 55131, Germany
    Recruiting
  • Klinikum Rechts Der Isar Der Technischen Universitaet Muenchen (Hopital Rechts Der Isar)
    München, 81675, Germany
    Recruiting
  • University Hospital Muenster
    Münster, 48149, Germany
    Recruiting
  • Clinexpert
    Budapest, 01033, Hungary
    Recruiting
  • Debreceni Egyetem Klinikai Kozpon Belgyogy Klinika
    Debrecen, 04032, Hungary
    Recruiting
  • University of Pecs-Clinical Center
    Pécs, 07632, Hungary
    Recruiting
  • University of Szeged
    Szeged, 06720, Hungary
    Recruiting
  • A.O. Policlinico Sant'Orsola Malpighi-Universita Degli Studi Di Bologna
    Bologna, 40138, Italy
    Recruiting
  • Azienda Ospedaliera Spedali Civili Di Brescia-Universita Degli Studi Di Brescia
    Brescia, 25123, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele Ospedale Gaspare Rodolico Di Catania
    Catania, 95123, Italy
    Recruiting
  • Uoc Dermatologia Ospedale Maggiore Policlinico, Fondazione Irccs Ca' Granda
    Milan, 20122, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Federico Ii Di Napoli
    Naples, 80131, Italy
    Recruiting
  • Azienda Ospedale Universita Di Padova
    Padua, 35100, Italy
    Recruiting
  • Istituto Di Ricovero E Cura A Carattere Scientifico (Ircss)
    Roma, 00167, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli Irccs
    Rome, 00137, Italy
    Recruiting
  • Irccs Ospedale Pediatrico Bambino Gesu
    Rome, 00165, Italy
    Recruiting
  • Amsterdam Umc Research Bv
    Amsterdam, 1105 AZ, Netherlands
    Recruiting
  • Centrum Badan Klinicznych Pi-House Sp. Z O.O.
    Gdansk, 80-546, Poland
    Recruiting
  • Care Clinic Sp. Z O.O.
    Katowice, 40-568, Poland
    Recruiting
  • Diamond Clinic Specjalistyczne Poradnie Lekarskie
    Krakow, 31-559, Poland
    Recruiting
  • Dermedic Iwona Zdybska
    Lublin, 20-607, Poland
    Recruiting
  • Twoja Przychodnia - Medyczne Nowa Sol
    Nowa Sól, 67-100, Poland
    Recruiting
  • Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski
    Osielsko, 86-031, Poland
    Recruiting
  • Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W Rzeszowie
    Rzeszów, 35-055, Poland
    Recruiting
  • Twoja Przychodnia Scm
    Szczecin, 71-500, Poland
    Recruiting
  • Evimed Sp. Z O. O.
    Warsaw, 02-625, Poland
    Recruiting
  • Centro Hospitalar E Universitario Coimbra
    Coimbra, 3000-075, Portugal
    Recruiting
  • Centro Hospitalar de Lisboa Central - Hospital Santo Antonio Dos Capuchos
    Lisbon, 1169-050, Portugal
    Recruiting
  • Hospital Geral de Santo Antonio
    Porto, 4099-001, Portugal
    Recruiting
  • Hospital Universitario Fundacion Alcorcon
    Alcorcón, 28922, Spain
    Recruiting
  • Hospital Universitari Germans Trias I Pujol
    Badalona, 08916, Spain
    Recruiting
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08026, Spain
    Recruiting
  • Hospital Sant Joan de Deu Barcelona
    Esplugues de Llobregat, 08950, Spain
    Recruiting
  • Hospital Infantil Unversitario Nino Jesus
    Madrid, 28009, Spain
    Recruiting
  • Hospital Universitario Miguel Servet de Zaragoza
    Zaragoza, 50009, Spain
    Recruiting
  • The Royal London Hospital - Barts Health Nhs Trust
    London, E1 1FR, United Kingdom
    Recruiting
  • Guys Hospital
    London, SE1 9RT, United Kingdom
    Recruiting
  • Great Ormond Street Hospital For Children Nhs Foundation Trust
    London, WC1N 3JH, United Kingdom
    Recruiting
  • Sheffield Childrens Hospital
    Sheffield, S10 2TH, United Kingdom
    Recruiting
  • Manor Hospital (Walsall) - Walsall Healthcare Nhs Trust
    Walsall, WS2 9PS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 3, 2025
StartActual
Nov 13, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Polyclinique de Courlancy · Reims, FranceNot yet recruiting→Recruiting
  • Irccs Ospedale Pediatrico Bambino Gesu · Rome, ItalyNot yet recruiting→Recruiting
  • Guys Hospital · London, United KingdomNot yet recruiting→Recruiting
  • Great Ormond Street Hospital For Children Nhs Foundation Trust · London, United KingdomNot yet recruiting→Recruiting
  • Manor Hospital (Walsall) - Walsall Healthcare Nhs Trust · Walsall, United KingdomNot yet recruiting→Recruiting
Show 1 removed
  • Croydon University Hospital · Croydon, United Kingdom
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site removed. 5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Polyclinique de Courlancy · Reims, FranceNot yet recruiting→Recruiting
    • Irccs Ospedale Pediatrico Bambino Gesu · Rome, ItalyNot yet recruiting→Recruiting
    • Guys Hospital · London, United KingdomNot yet recruiting→Recruiting
    • Great Ormond Street Hospital For Children Nhs Foundation Trust · London, United KingdomNot yet recruiting→Recruiting
    • Manor Hospital (Walsall) - Walsall Healthcare Nhs Trust · Walsall, United KingdomNot yet recruiting→Recruiting
    Show 1 removed
    • Croydon University Hospital · Croydon, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06804811
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Nov 13, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion